Chodyla Michal, Demircioglu Aydin, Schaarschmidt Benedikt M, Bertram Stefanie, Morawitz Janna, Bauer Sebastian, Podleska Lars, Rischpler Christoph, Forsting Michael, Herrmann Ken, Umutlu Lale, Grueneisen Johannes
Department of Diagnostic and Interventional Radiology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany.
Cancers (Basel). 2021 Jun 1;13(11):2753. doi: 10.3390/cancers13112753.
To evaluate the potential of simultaneously acquired 18F-FDG PET- and MR-derived quantitative imaging data sets of primary soft-tissue sarcomas for the prediction of neoadjuvant treatment response, the metastatic status and tumor grade.
A total of 52 patients with a high-risk soft-tissue sarcoma underwent a 18F-FDG PET/MR examination within one week before the start of neoadjuvant treatment. For each patient, the maximum tumor size, metabolic activity (SUVs), and diffusion-restriction (ADC values) of the tumor manifestations were determined. A Mann-Whitney-U test was used, and ROC analysis was performed to evaluate the potential to predict histopathological treatment response, the metastatic status or tumor grade. The results from the histopathological analysis served as reference standard.
Soft-tissue sarcomas with a histopathological treatment response revealed a significantly higher metabolic activity than tumors in the non-responder group. In addition, grade 3 tumors showed a significant higher 18F-FDG uptake than grade 2 tumors. Furthermore, no significant correlation between the different outcome variables and tumor size or calculated ADC-values could be identified.
Measurements of the metabolic activity of primary and untreated soft-tissue sarcomas could non-invasively deliver relevant information that may be used for treatment planning and risk-stratification of high-risk sarcoma patients in a pretherapeutic setting.
为评估同时获取的原发性软组织肉瘤的18F-FDG PET和磁共振成像(MR)衍生的定量成像数据集在预测新辅助治疗反应、转移状态和肿瘤分级方面的潜力。
共有52例高危软组织肉瘤患者在新辅助治疗开始前一周内接受了18F-FDG PET/MR检查。对于每位患者,确定肿瘤表现的最大肿瘤大小、代谢活性(SUV值)和扩散受限情况(表观扩散系数[ADC]值)。采用曼-惠特尼U检验,并进行ROC分析,以评估预测组织病理学治疗反应、转移状态或肿瘤分级的潜力。组织病理学分析结果作为参考标准。
组织病理学治疗有反应的软组织肉瘤比无反应组的肿瘤代谢活性显著更高。此外,3级肿瘤的18F-FDG摄取显著高于2级肿瘤。此外,未发现不同结果变量与肿瘤大小或计算出的ADC值之间存在显著相关性。
对原发性未经治疗的软组织肉瘤代谢活性的测量可以无创地提供相关信息,这些信息可用于治疗前环境下高危肉瘤患者的治疗规划和风险分层。